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A hospital-based case-control study of identifying 
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Objective: Recently, a symptom index for identification of ovarian cancer, based on specific symptoms along with their 
frequency and duration, was proposed. The current study aimed at validation of this index in Korean population. 
Methods: A case-control study of 116 women with epithelial ovarian cancer and 209 control women was conducted 
using questionnaires on eight symptoms. These included pelvic/abdominal pain, urinary urgency/frequency, increased 
abdominal size/bloating, difficulty eating/feeling full. The symptom index was considered positive if any of the 8 
symptoms present for ＜1 year that occurred＞12 times per month. The symptoms were compared between ovarian 
cancer group and control group using chi-square test. Logistic regression analysis was used to determine whether the 
index predicted cancer. Sensitivity and specificity of the symptom index were also determined.
Results: The symptom index was positive in 65.5% of women with ovarian cancer, in 31.1% of women with benign 
cysts, and in 6.7% of women on routine screening (ps＜0.001). Significantly higher proportion of ovarian cancer 
patients were positive for each symptom as compared with control group (ps＜0.001). Results from the logistic 
regression indicated that the symptom index independently predicted cancer (p＜0.001; OR, 10.51; 95% CI, 6.14 to 
17.98). Overall, the sensitivity and specificity of the symptom index were 65.5% and 84.7%, respectively. Analyses of 
sensitivity by stage showed that the index was positive in 44.8% of patients with stage I/II disease and in 72.9% of 
patients with stage III/IV disease.
Conclusion: The current study supported previous studies suggesting that specific symptoms were useful in 
identifying women with ovarian cancer.
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INTRODUCTION
Ovarian cancer is the second most common gynecologic ma-
lignancy worldwide and, unfortunately, the mortality rate is al-
so high.1 One of the reasons for the high fatality rate is that more 
than two-thirds of ovarian cancer cases are diagnosed with ad-
vanced-stage disease. Five-year survival rates of advanced- 
stage disease are only 20% to 30%, whereas those for early stage 
disease are 70% to 90%. To improve the survival, several at-
tempts to develop screening strategies to diagnose ovarian can-
cer in earlier stage have been made. However, available screen-
ing tools, CA-125 and transvaginal ultrasound, have not shown 
to be sensitive and specific enough to recommend for the gen-
eral population. 
Due to the current limitations of screening, several inves-
tigators have tried to identify specific symptoms as a potential 
method for early detection of the disease.2-5 Studies of symp-
toms have confirmed that women with ovarian cancer have gas-
trointestinal, abdominal, and urinary symptoms. Such symp-
toms are often vague, and many false positive results may occur. 
But, Goff et al.6 advocated that symptoms are more recent and 
greater in severity and frequency in women with ovarian cancer 
than in those without. Moreover, the authors suggested a symp-
tom index composed of six symptoms along with their fre-
quency and duration to be useful for identifying women at risk.7 
However, the symptom index has not been validated in an in-
dependent patient cohort. The aim of this study was to validate 
the symptom index in Korean population. 
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Table 1. Characteristics of ovarian cancer patients and controls
Characteristics No. of patients (%)
Ovarian cancer patients (N=116)
 Median age (range)
 Stage
   I
   II
   III
   IV
 Histology
   Serous
   Mucinous
   Endometrioid
   Clear cell
   Others
Benign ovarian cyst (N=74)
 Median age (range)
 Histology
   Teratoma
   Endometriotic cyst
   Cystadenoma
   Others
Routine screening (clinic, N=135)





















From July 2007 through February 2008, a symptom survey 
of women who visited the gynecologic oncology department 
in our hospital was carried out using questionnaires based on 
symptoms of the ovarian cancer symptom index suggested by 
Goff et al. Participants included women who were diagnosed 
to have ovarian cancer (cancer group), women who under-
went surgery for benign ovarian cysts (benign cyst group), and 
women who visited our department for routine Pap smear 
with at least one intact ovary and uterus (clinic group). From 
clinic group, women who had history of gynecologic malig-
nancies were excluded. Both ovarian cancer group and benign 
cyst group were histologically confirmed. Benign cyst group 
and clinic group constituted the control group. 
All participants were asked to complete an identical question-
naire about the occurrence of 8 symptoms, which included pelvic/ 
abdominal pain, urinary urgency/frequency, increased abdomi-
nal size/bloating, and difficulty eating/feeling full, along with 
the frequency and duration of symptoms. A symptom index was 
considered positive if a woman had any of the 8 symptoms present 
for ＜1 year that occurred ＞12 times per month. We included 
eight symptoms in this survey, which added urinary symptoms to 
Goff’s original symptom index. Urinary symptoms were deleted 
from Goff’s index in selection of the most sensitive model. How-
ever, we included urinary symptoms which have been suggested 
to be significantly related to ovarian cancer in several studies as 
well as Goff’s study. In benign cyst group, surveys were done 
before operation. Whereas, in ovarian cancer group, surveys were 
done during hospital stays for operation or for chemotherapy. 
Participants were instructed to fill out the questionnaire by 
themselves. But, in case participants could not understand the 
questions fully, investigators were allowed to explain them. 
Preoperative CA-125 level was assessed in almost all pa-
tients in ovarian cancer and benign cyst group. In our in-
stitution, the cut-off value for CA-125 level is 37 U/ml. When 
analyzing the combination of CA-125 test and symptom in-
dex, it was considered suggestive of ovarian cancer if either 
CA-125 test or symptom index was positive. 
Statistical analysis was performed using SPSS ver. 12.0 (SPSS 
Inc., Chicago, IL, USA). The symptoms were compared be-
tween the patient groups using chi-square test. When the ques-
tionnaire was not filled completely, the unanswered variable 
was processed into missing value. Odds ratios (ORs) of each 
symptom variable for ovarian cancer were calculated by logistic 
regression analysis. In addition, a multivariate logistic re-
gression was performed to determine which of the four symp-
toms would remain independently significant. Sensitivity and 
specificity of the symptom index were also determined. For all 
analyses, p＜0.05 was considered statistically significant.
RESULTS
Three hundred and twenty-five women participated in this 
survey. Participants were composed of 116 women with ovar-
ian cancer, 74 women with benign ovarian cysts, and 135 
women on routine Pap smear. Median ages of ovarian cancer, 
benign cyst, and routine screening patients were 54, 35.5, and 
51 years, respectively (Table 1). Two-thirds of ovarian cancer 
patients had advanced diseases (III 55.3%; IV 19.3%). In be-
nign cyst group, endometriotic cyst was the most frequent di-
agnosis (45.9%) followed by teratoma (29.7%). 
In ovarian cancer group, the median time from diagnosis to 
interview was 3.17 months (range, -3 to 84 months), and 66% 
were interviewed within 6 months. Because some patients were 
surveyed years after the diagnosis, we analyzed the symptoms 
separately for those diagnosed within 6 months and those diag-
nosed ＞6 months from the survey to determine whether the 
data were affected by significant recall bias. There was not a sig-
nificant difference in the rates of positive index between the two 
groups of cancer patients (p=0.169). 
Seventy-six ovarian cancer patients (76/116, 65.5%) had a 
positive symptom index, whereas the index was positive in 23 
benign cyst patients (23/74, 31.1%) and 9 routine screening 
patients (9/135, 6.7%) (ps＜0.001, Table 2). For each symptom, 
significantly higher proportion of ovarian cancer patients were 
positive as compared with clinic group (ps＜0.001) (Table 2). 
When we compared the symptoms between cancer and benign 
cyst group, symptoms were significantly more prevalent in 
cancer patients, except pelvic/abdominal pain (17.2% in cancer 
vs. 13.5% in benign cyst group; p=0.492). The high prevalence 
of endometriotic cyst may explain the frequency of pelvic/ab-
dominal pain in benign cyst group.
Results from the logistic regression indicated that the symptom 
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Table 3. Results of logistic regression analysis













OR: odds ratio, CI: confidence interval.
Table 4. Results of multivariate logistic regression analysis







OR: odds ratio, CI: confidence interval.





















































Values are presented as number (%).
index independently predicted cancer (p＜0.001; OR, 10.51; 
95% CI, 6.14 to 17.98). When analyzed four symptom varia-
bles separately, increased abdominal size/bloating and uri-
nary urgency/frequency were statistically significant pre-
dictors of ovarian cancer (Table 3). After multivariate analy-
sis, the two symptom variables remained independently sig-
nificant (Table 4). In particular, urinary symptom was a sig-
nificant predictor in our study, which was not included in the 
symptom index of Goff et al. in selecting the model with the 
greatest sensitivity. In our study, however, the sensitivity de-
creased from 65.5% to 56.9% with a similar specificity of 
87.6% using the symptom index composed of 6 symptoms 
without urinary symptoms. This can be said that urinary 
symptom was more frequently reported by ovarian cancer pa-
tients in Korean population.
Overall, the sensitivity and specificity of the symptom index 
were 65.5% and 84.7%, respectively. This result was com-
parable to that of the study of Goff et al. Analyses of sensitivity 
by stage showed that the index was positive in 44.8% of pa-
tients with stage I/II disease and in 72.9% of patients with 
stage III/IV disease. When stratified by age, the sensitivity 
was 81.9% with a specificity of 58.5% for women aged＜50 
years. For women aged ≥50 years, the sensitivity was 69.3% 
and the specificity was 89.0%. 
When we combined CA-125 level and symptom index, the 
sensitivity rose to 85.3% while the specificity decreased to 
59.5%. In ovarian cancer patients who did not have elevated 
CA-125 levels, 5 out of 11 cases (45.5%) were additionally 
identified with the symptom index. Unfortunately, 30.5% 
(18/59 patients) of benign cyst patients with normal CA-125 
levels also demonstrated a positive symptom index score. 
DISCUSSION
The current study supported previous studies suggesting 
that specific symptoms were useful in identifying women with 
ovarian cancer.2-5,8 In addition, this study validated the ovar-
ian cancer symptom index developed by Goff et al. in Korean 
population. The sensitivity and the specificity of the symptom 
index in our study were 65.5% and 84.7%, respectively. This 
was consistent with the findings of Goff’s study. In addition, 
the symptom index was comparable to CA-125 test, which 
has sensitivity that ranges from 50% to 79% and specificity 
that ranges from 96% to 99%.9,10 
Researches on specific symptoms for early detection of ovar-
ian cancer started from the limitations of available screening 
strategies, such as CA-125 and transvaginal ultrasonography. 
Although a UK pilot study in 199911 showed a survival benefit 
for screening using CA-125 and transvaginal ultrasonography, 
there has been no confirmatory result to support routine 
screening for the general population. The final results of UK 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) 
will not be known until 2014.12 Consequently, until there is a 
valid screening tool, several researchers suggested that symp-
toms associated with ovarian cancer may serve as another op-
tion for early detection. In several retrospective studies, more 
than 90% of women with ovarian cancer do have at least one 
symptom.2-6 The symptoms most commonly seen are abdomi-
nal or gastrointestinal in nature, whereas gynecologic symp-
toms, such as abnormal vaginal bleeding or menstrual irregu-
larities, were reported by less than 25% of patients.5,13,14
These symptoms tend to be more constant and of more re-
cent onset. With accumulating evidences, finally in 2007, sev-
eral US organizations, including patient groups, released a 
consensus statement on the symptoms of ovarian cancer.15 
The statement urges women to seek medical attention if they 
have new and persistent symptoms of bloating, pelvic or ab-
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dominal pain, difficulty eating or early satiety, and urinary ur-
gency or frequency. Recently, it was further supported by 
Hamilton et al who reported that these symptoms are also in-
dependently associated with ovarian cancer in women pre-
senting to primary care similarly to hospital series.16
In this context, Goff et al. developed an ovarian cancer symp-
tom index including 6 symptoms (pelvic/abdominal pain, in-
creased abdominal size/bloating, and feeling full/difficulty 
eating) to implement widespread awareness of ovarian cancer 
symptoms and are currently in the process of examining the 
index in a prospective fashion in a primary care setting.7 They 
advocated that this tool can be useful in early detection of 
ovarian cancer and that, through diagnosing cancer 3 to 6 
months earlier, the symptom index might be able to favorably 
affect the survival. However, caution should be paid about the 
view of potential survival benefit from early detection through 
recognizing those symptoms. There have been several studies 
refuting the suggestion that delay in diagnosis is responsible 
for the advanced disease.2,13,17,18 In these studies, women with 
early stage disease reported similar or rather longer duration 
of symptoms, indicating there may be significant biological 
differences between the early and advanced stages. Never-
theless, Goff’s symptom index is meaningful in that it made 
patients and clinicians aware of specific symptoms as early 
alarm. 
When combining CA-125 and symptom index, the sensitivity 
increased from 65.5% to 85.3% in our study. Unfortunately, 
however, the specificity of the combination test dropped to 
59.5%. Although we only included women who received oper-
ations for cancer or benign cyst in this analysis, our result was 
similar to the study of Andersen et al.19 In spite of the low spe-
cificity of the combination of CA-125 and symptom index, 
this strategy is worthy of further research in larger population 
because high sensitivity is critical in first-line screening. In ad-
dition, using transvaginal ultrasonography as a second-stage 
test, false positive findings can be identified before referral for 
surgery, achieving adequate positive predictive value. A po-
tential limitation of our study is recall bias, even though there 
was not a significant difference in response between the pa-
tients diagnosed within 6 months and those diagnosed ＞6 
months from the survey. Although we tried to survey patients 
as early as possible from diagnosis, the majority of ovarian 
cancer patients were interviewed after surgery and during the 
courses of chemotherapy. However, this study is meaningful 
in that symptoms were directly obtained from patients, not 
from medical records. Recall bias can be resolved only in sub-
sequent prospective studies. Another limitation of this study 
is that this survey was conducted in a secondary care setting. 
To overcome this limitation, we included women who visited 
the general gynecology subdivision in the gynecologic oncol-
ogy department for routine Pap smear in the clinic group. 
Although these women may represent the women in primary 
care settings to some extent, following validation studies in 
primary care settings are still needed. In addition, the discrep-
ancy in age distribution between the three groups might affect 
the results of this study. 
The symptom index is not sufficient to be recommended as 
a screening tool as yet. However, when the patients complain 
about recent and persistent abdominal, gastrointestinal or 
urinary symptoms, it is important for attending physicians to 
have a suspicion and to perform pelvic examinations. Pelvic 
examinations do not add to the medical costs, and trans-
vaginal ultrasonography, when needed, does not cause sig-
nificant discomforts to patients. Until there is a valid screen-
ing test, the symptom index may serve as a useful and inex-
pensive tool to identify patients who need further evaluations. 
In future studies, the utility of these symptoms in general pop-
ulation needs to be evaluated in prospective settings.
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